Drug Type Monoclonal antibody |
Synonyms Anti-interleukin 17A monoclonal antibody, Scapho, Secukinumab (Genetical Recombination) + [8] |
Target |
Action inhibitors |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (26 Dec 2014), |
RegulationOrphan Drug (United States), Priority Review (China), Overseas New Drugs Urgently Needed in Clinical Settings (China), Orphan Drug (Japan) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09967 | Secukinumab |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pustular psoriasis | Japan | 21 Dec 2015 | |
Ankylosing Spondylitis | Australia | 12 Jan 2015 | |
Axial Spondyloarthritis | Australia | 12 Jan 2015 | |
Enthesitis-Related Arthritis | Australia | 12 Jan 2015 | |
Hidradenitis Suppurativa | Australia | 12 Jan 2015 | |
Juvenile Idiopathic Arthritis | Australia | 12 Jan 2015 | |
Non-radiographic axial spondyloarthritis | Australia | 12 Jan 2015 | |
Plaque psoriasis | Australia | 12 Jan 2015 | |
Arthritis, Psoriatic | Japan | 26 Dec 2014 | |
Psoriasis vulgaris | Japan | 26 Dec 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Polymyalgia Rheumatica | Phase 3 | United States | 22 Mar 2023 | |
Polymyalgia Rheumatica | Phase 3 | Japan | 22 Mar 2023 | |
Polymyalgia Rheumatica | Phase 3 | Argentina | 22 Mar 2023 | |
Polymyalgia Rheumatica | Phase 3 | Australia | 22 Mar 2023 | |
Polymyalgia Rheumatica | Phase 3 | Belgium | 22 Mar 2023 | |
Polymyalgia Rheumatica | Phase 3 | Brazil | 22 Mar 2023 | |
Polymyalgia Rheumatica | Phase 3 | Canada | 22 Mar 2023 | |
Polymyalgia Rheumatica | Phase 3 | Chile | 22 Mar 2023 | |
Polymyalgia Rheumatica | Phase 3 | Colombia | 22 Mar 2023 | |
Polymyalgia Rheumatica | Phase 3 | Czechia | 22 Mar 2023 |
Phase 3 | 84 | znyxwahnii(zyqzpfwcea) = ihuyogqmba wgpeeusseh (sqaerydzqu ) View more | Positive | 28 Aug 2025 | |||
Secukinumab HD | znyxwahnii(zyqzpfwcea) = qersspiprt wgpeeusseh (sqaerydzqu ) View more | ||||||
Phase 3 | 771 | Secukinumab 300 mg every 2 weeks | rdnnwuvkmh(jnnynojuxg) = At Week 16, exposure overlap was high, with an estimated numerical increase in HiSCR of ~3% for SECQ2W over SECQ4W. At Week 52, HiSCR levels plateaued. yxnhargdnc (idbwosvgca ) View more | Positive | 21 Aug 2025 | ||
Secukinumab 300 mg every 4 weeks | |||||||
Phase 3 | 1,084 | Secukinumab 300 mg every 2 weeks | ebguwoycir(panttfpgme) = ndzhrphhpr fmzvgkmpfw (libhwgbafr ) View more | Positive | 01 Aug 2025 | ||
Secukinumab 300 mg every 4 weeks | ebguwoycir(panttfpgme) = xqhprpqrko fmzvgkmpfw (libhwgbafr ) View more | ||||||
Phase 3 | - | Cosentyx + 糖皮质激素 | uandlhdzkj(xwvebngbnx) = Cosentyx在52周时的持续缓解率未达到统计学显著性差异。 wuhpupbufr (icxullgwbb ) Not Met | Negative | 04 Jul 2025 | ||
Placebo + 糖皮质激素 | |||||||
Not Applicable | 32 | ftoonvvwai(dwgnoxqptd) = significant decrease compared to baseline ddbxpgaugj (kvqltpvmby ) View more | Positive | 11 Jun 2025 | |||
Not Applicable | 1,085 | (PsA) | igjfjskkea(xfvpdqfpxj) = pakkvwqnsz wytketpfwd (ceoomxubpy ) View more | Positive | 11 Jun 2025 | ||
(r-axSpA) | igjfjskkea(xfvpdqfpxj) = apypojlsmt wytketpfwd (ceoomxubpy ) View more | ||||||
Phase 3 | 55 | (Group 1- Secukinumab 75 mg) | dofwojryjp = qdzdfcylan pywmuyqsie (xkmscfnero, dwkktihplz - qbzqbjwvpn) View more | - | 23 May 2025 | ||
(Group 2 - Secukinumab 150 mg) | dofwojryjp = pdjbzoebfn pywmuyqsie (xkmscfnero, fmtjiwhutx - fyszckqvgi) View more | ||||||
Phase 3 | 28 | (Secukinumab 300 mg) | ejmaxydrqx(rzsrwmwtuh) = tuntqlizqs zkafsclsew (navuqjozzd, 0.58) View more | - | 09 Jan 2025 | ||
Placebo (Placebo) | ejmaxydrqx(rzsrwmwtuh) = byeeltlpwy zkafsclsew (navuqjozzd, 0.47) View more | ||||||
Phase 3 | Hidradenitis Suppurativa Maintenance | - | Secukinumab 300 mg every 2 weeks | mhrfmqlpyw(feiehrvsei) = iqqqihluee qzkievceaf (rsnikdlfjp, 176 - -) View more | Negative | 29 Nov 2024 | |
Secukinumab 300 mg every 4 weeks | mhrfmqlpyw(feiehrvsei) = wqyrswuhnq qzkievceaf (rsnikdlfjp, 225 - -) View more | ||||||
Phase 3 | 288 | nejvbgetxk(urlidlupgy) = The mean total spine BME score at baseline was higher in moderate to fast progressors vs non to slow progressors. A decrease in BME from baseline to W16 was seen in both subgroups, which remained consistent thereafter up to W104, remaining higher in moderate to fast progressors. jgdzrdvrtp (grkymwdaud ) View more | Positive | 10 Nov 2024 | |||